EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Arianne Morissette, Erin E Mulvihill

Journal of Pharmacy & Pharmaceutical Sciences · 06.06.2024 · 27

DOI: 10.3389/jpps.2024.13065 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 06.06.2024. Verfasst von Arianne Morissette und 1 weiteren Autor:innen. Beteiligte Einrichtung: The University of Ottawa Heart Institute, Ottawa, ON, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Bariatric Surgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden. Traditionally viewed as a chronic and irreversible condition, T2DM management has evolved and new approaches emphasizing reversal and remission are emerging. Bariatric surgery demonstrates significant improvements in body weight and glucose homeostasis. However, its complexity limits widespread implementation as a population-wide intervention. The identification of glucagon-like peptide 1 (GLP-1) and the development of GLP-1 receptor agonists (GLP-1RAs) have improved T2DM management and offer promising outcomes in terms of weight loss. Innovative treatment approaches combining GLP-1RA with other gut and pancreatic-derived hormone receptor agonists, such as glucose-dependant insulinotropic peptide (GIP) and glucagon (GCG) receptor agonists, or coadministered with amylin analogues, are demonstrating enhanced efficacy in both weight loss and glycemic control. This review aims to explore the benefits of bariatric surgery and emerging pharmacological therapies such as GLP-1RAs, and dual and triple agonists in managing obesity and T2DM while highlighting the caveats and evolving landscape of treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityBariatric SurgeryHumansHypoglycemic AgentsGlucagon-Like Peptide 1Weight LossObesity ManagementGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

glucagon like peptide 1gut hormonesmetabolic surgeryobesitytype 2 diabetes mellitus

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • The University of Ottawa Heart Institute, Ottawa, ON, Canada.
  • Department of Biochemistry, Microbiology and Immunology, The University of Ottawa, Faculty of Medicine, Ottawa, ON, Canada.

Zitieren

APA

Morissette, A., & Mulvihill, E. E. (2024). Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches. Journal of Pharmacy & Pharmaceutical Sciences, 27. https://doi.org/10.3389/jpps.2024.13065

Vancouver

Morissette A, Mulvihill EE. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches. Journal of Pharmacy & Pharmaceutical Sciences. 2024;27. doi:10.3389/jpps.2024.13065

BibTeX
@article{Morissette2024,
  author = {Morissette, Arianne and Mulvihill, Erin E},
  title = {Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2024},
  volume = {27},
  doi = {10.3389/jpps.2024.13065}
}
Kostenlos starten →